Arbe Announces Second Quarter 2026 Financial Results

Arbe Robotics Ltd. (NASDAQ: ARBE) reported Q2 2026 results for the quarter ended June 30, 2026. Revenues rose to $0.7 million from $0.3 million a year earlier, with operating expenses of $9.8 million and net loss of $9.1 million. Cash was about $41.9 million. Full-year 2026 outlook: revenue $4-$6 million and adjusted EBITDA loss $28-$31 million.

Original reporting
Published Aug 6, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Arbe Announces Second Quarter 2026 Financial Results — source image
Decision brief

The 30-second read

$ARBENeutralMed
01

Why it matters

Q2 results and reaffirmed 2026 outlook provide a fresh checkpoint on commercialization progress, cash runway, and cost discipline, which can drive valuation and risk-premium changes.

02

Market read

Investors get a concrete update on revenue scale, operating loss trajectory, and liquidity runway, plus reaffirmed full-year targets and a cost-burn timeline.

03

What to watch

The company emphasizes a 15% expense reduction expected to fully hit in Q3 and targets cash burn below $7M per quarter; traders may underweight how quickly burn reduction could extend runway and affect dilution risk.

Relevance 8/10Novelty 7/10Timing: pre-market today, with an 8:30 a.m. ET conference call

Background

Arbe is transitioning from a radar chipset supplier toward a complete radar technology provider, targeting shorter sales cycles in automotive and defense.

Company-level read

Ticker impact

$ARBENeutralMedium confidence
Context

Arbe reported Q2 2026 results and reaffirmed 2026 guidance, including revenue of $0.7M and an adjusted EBITDA loss outlook of $28M to $31M.

Expected impact

Near-term volatility likely tied to whether investors view the $0.7M revenue and reaffirmed guidance as credible progress toward profitability.

Evidence & confidence

This is a primary earnings/guidance disclosure with specific liquidity and expense details, but the absolute revenue scale remains small and backlog is limited ($1M), which can cap upside expectations.

Market effects

Adds datapoint on ultra-high-resolution radar commercialization timelines across automotive robotaxi and defense programs.

Limited direct regional spillover beyond Israel-based defense/tech investor sentiment.

Relevant to autonomy and sensing supply-chain expectations, but scale is small versus large autonomy peers.

Counterpoint

Despite revenue growth, backlog remains only $1M and robotaxi/OEM adoption cycles are taking longer, so the guidance may be conservative and execution risk remains high.

Key entities

  • Arbe Robotics Ltd.

    NASDAQ-listed ultra-high-resolution radar company reporting Q2 2026 financial results and reaffirming 2026 guidance.

  • Kobi Marenko

    President and co-founder who commented on on-road robotaxi trials and started defense deliveries.

  • Ram Machness

    CEO who attributed revenue growth to diversified markets and shorter sales cycles.

  • HiRain

    Tier 1 radar supplier progressing toward production planned for early 2027, tied to an L4 OEM order.

Related articles

$WESTHigh

Westrock Coffee falls as Q3 sales miss estimates (WEST:NASDAQ)

Westrock Coffee (WEST) reported Q3 sales below estimates, with a wider net loss than expected. Shares fell 12% despite growth in adjusted EBITDA and gross profit. The company kept its full-year earnings forecast and provided an initial outlook. According to the company, sales were $1.2B vs. $1.3B expected, with a net loss of $0.15 per share vs. $0.05 expected.

$NETHighAI 8/10

Cloudflare Just Had Its “Best Quarter Ever” on the Day Tech Crashed

Cloudflare (NET) reported strong Q3 2026 earnings, with revenue of $782.5M (+39% YoY) and non-GAAP EPS of $0.38, beating estimates. Despite a 21.2% weekly decline, shares rose 14.72% after-hours. The company raised full-year revenue guidance to $2.963B-$2.964B and expects GAAP profitability in Q4, earlier than previously forecasted. Key metrics like dollar-based net retention (122%) and remaining performance obligations ($2.877B) also improved.

$SANAHighAI 8/10

Sana Biotechnology Reports Q3 Profit; Advances Cell Therapy Programs Toward Clinical Trials

Sana Biotechnology (SANA) reported Q3 2026 net income of $20.4M, with R&D expenses rising to $33.9M. The company has $121.7M in cash, expecting a runway into mid-2027. SANA advanced cell therapy programs for type 1 diabetes and non-Hodgkin lymphoma, targeting clinical trials in 2026-2027. UP421 showed long-term survival in type 1 diabetes study. SANA stock is up 1.75% to $2.38.